Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells

T Lymphocytes Redirected against the Chondroitin Sulfate Proteoglycan-4 Control the Growth of Multiple Solid Tumors both In Vitro and In Vivo

(2013) C. Geldres et al.   CLINICAL CANCER RESEARCH

Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy

(2013) Richard A. Morgan et al.   JOURNAL OF IMMUNOTHERAPY

Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity

(2013) Cor HJ Lamers et al.   MOLECULAR THERAPY

Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors

(2013) James N. Kochenderfer et al.   Nature Reviews Clinical Oncology

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

(2013) Stephan A. Grupp et al.   NEW ENGLAND JOURNAL OF MEDICINE

CSPG4 as a Target of Antibody-Based Immunotherapy for Malignant Mesothelioma

(2012) Z. Rivera et al.   CLINICAL CANCER RESEARCH

Recognition of Glioma Stem Cells by Genetically Modified T Cells Targeting EGFRvIII and Development of Adoptive Cell Therapy for Glioma

(2012) Richard A. Morgan et al.   HUMAN GENE THERAPY

Protein L: a novel reagent for the detection of Chimeric Antigen Receptor (CAR) expression by flow cytometry

(2012) Zhili Zheng et al.   Journal of Translational Medicine

Expression of the progenitor marker NG2/CSPG4 predicts poor survival and resistance to ionising radiation in glioblastoma

(2011) Agnete Svendsen et al.   ACTA NEUROPATHOLOGICA

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

(2011) J. N. Kochenderfer et al.   BLOOD

CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo

(2011) D.-G. Song et al.   BLOOD

Functional Characterization of an scFv-Fc Antibody that Immunotherapeutically Targets the Common Cancer Cell Surface Proteoglycan CSPG4

(2011) X. Wang et al.   CANCER RESEARCH

Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1

(2011) Paul F. Robbins et al.   JOURNAL OF CLINICAL ONCOLOGY

Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

(2011) David L. Porter et al.   NEW ENGLAND JOURNAL OF MEDICINE

CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma

(2011) Matthew A. Price et al.   Pigment Cell & Melanoma Research

Treating cancer with genetically engineered T cells

(2011) Tristen S. Park et al.   TRENDS IN BIOTECHNOLOGY

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19

(2010) J. N. Kochenderfer et al.   BLOOD

Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor

(2010) B. Jena et al.   BLOOD

A High Molecular Weight Melanoma-Associated Antigen-Specific Chimeric Antigen Receptor Redirects Lymphocytes to Target Human Melanomas

(2010) W. R. Burns et al.   CANCER RESEARCH

CSPG4 in Cancer: Multiple Roles

(2010) X. Wang et al.   CURRENT MOLECULAR MEDICINE

CSPG4 Protein as a New Target for the Antibody-Based Immunotherapy of Triple-Negative Breast Cancer

(2010) Xinhui Wang et al.   JNCI-Journal of the National Cancer Institute

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

(2010) Richard A Morgan et al.   MOLECULAR THERAPY

T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis

(2010) Maria R Parkhurst et al.   MOLECULAR THERAPY

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

(2009) L. A. Johnson et al.   BLOOD

A Herceptin-Based Chimeric Antigen Receptor with Modified Signaling Domains Leads to Enhanced Survival of Transduced T Lymphocytes and Antitumor Activity

(2009) Y. Zhao et al.   JOURNAL OF IMMUNOLOGY

NG2 expression predicts the metastasis formation in soft-tissue sarcoma patients

(2008) Maria Serena Benassi et al.   JOURNAL OF ORTHOPAEDIC RESEARCH